The Benign Prostatic Hyperplasia Registry and Patient Survey: study design, methods and patient baseline characteristics


Claus G. Roehrborn, The University of Texas Southwestern Medical Center at Dallas, Department of Urology, 5323 Harry Hines Boulevard, J8-142, Dallas, TX 75390–9110, USA. e-mail:


The first paper describes the design and baseline characteristics of patients in the BPH Registry and Patient Survey in the USA. This important study will provide information on management practices and outcomes of men with this condition, as well as examining the effects of demographics, socio-economics, comorbidities and medical therapies.

Another important study in the USA is the Boston Area Community Health Survey, and in this issue the authors estimate the future magnitude of urological symptoms in that country. They found that it might reach the current level of cardiovascular disease and suggested that this will have huge affects on health service policy.


To describe the design and baseline cohort characteristics of the Benign Prostatic Hyperplasia (BPH) Registry and Patient Survey, an ongoing, prospective, observational, disease registry documenting management practices and patient outcomes in men in the USA with lower urinary tract symptoms associated with BPH (LUTS/BPH) in actual clinical practice settings.


Men with LUTS/BPH who were either untreated or treated with α1-adrenergic blockers (ABs), 5α-reductase inhibitors (5ARIs), a combination of these medications, or anticholinergics, and who met selection criteria, were enrolled at sites throughout the USA. At each visit, standardized forms and validated questionnaires were completed to assess the physicians’ management practices and patients’ clinical characteristics, sexual function, and health-related quality of life.


At the close of recruitment (February 2005), 6909 men (mean age 66.0 years) were enrolled at 402 sites by urologists and primary-care physicians. Before enrolment, 49% of the men were managed with watchful waiting (WW), 21% with uroselective AB monotherapy, 11% with non-uroselective AB monotherapy, 6% with 5ARI monotherapy, 11% with AB + 5ARI, and 2% with anticholinergics. After enrolment, 42% were on WW and 26% were on selective AB monotherapy; changes in other management groups were minimal. Overall, 33% of the men had mild, 52% had moderate and 15% had severe LUTS. The most common comorbidities were hypertension (53%), high cholesterol (45%) and sexual dysfunction (36%).


The BPH Registry and Patient Survey will provide information on physician management practices and outcomes of men with LUTS/BPH, while examining the effects of demographics, socio-economics, comorbidities, and medical therapies.


α1-adrenergic blocker


5α-reductase inhibitor


body-mass index


BPH Registry and Patient Survey


Global Assessment Form


erectile dysfunction


Mental Component Score


Men’s Sexual Health Questionnaire


Physical Component Score


12-Item Short Form Health Survey


Sexual Health Inventory for Men


watchful waiting.


BPH is a common cause of morbidity in ageing men; depending on the degree of bother, men with BPH might complain of one or more LUTS, including increased frequency of urination, nocturia, hesitancy, urgency, straining, intermittency, dribbling, incomplete bladder emptying, and a weak urinary stream. The prevalence of histological BPH is 50% in men aged 51–60 years and increases to 90% in those aged 81–90 years [1]. BPH can be a progressive disease that might cause serious complications, including haematuria, recurrent UTIs, acute urinary retention and, rarely, renal insufficiency [2,3]. LUTS are also associated with sexual dysfunction, bother, worry and interference with daily activities. The results of population-based epidemiological studies show that LUTS are an independent risk factor for both erectile dysfunction (ED) and ejaculatory dysfunction [4,5]. Furthermore, men with moderate-to-severe LUTS report significant decreases in health-related quality of life, with 4–6 times the bother and interference with daily activities and twice the worry of men with mild LUTS [6]. Increased bother/decreased quality of life is the main reason that men seek help for LUTS associated with BPH (LUTS/BPH) and is a primary consideration in the treatment recommendations of the AUA BPH guideline [7]. Despite increased knowledge of the natural history and risk factors associated with LUTS/BPH, information on physician-practice patterns, the longitudinal relationship between LUTS, sexual function and quality of life, and patient outcomes is limited.

A disease registry provides a systematic and inclusive database of information on representative individuals with an identified category of disease from a defined population [8]. A disease registry offers various differences in design and capability from a clinical trial. Unlike a clinical trial, which evaluates efficacy, a disease registry evaluates the effectiveness of management practices. Although a clinical trial provides data that can be useful for evidence-based recommendations on patient care, a disease registry provides data on patient care in actual practice settings, and changes in management over time. Whereas a clinical trial is conducted in a controlled setting, treatment is pre-specified by protocol, patients are evaluated at specified intervals, and enrolment is restricted by pre-specified inclusion and exclusion criteria, a disease registry documents actual care, treatments are not specified by protocol, patient visits are not controlled, and enrolment criteria are usually broad. A disease registry also offers an opportunity to assess whether physicians adhere to the practice guidelines recommended by speciality groups, societies and governmental organizations. Accordingly, data from a disease registry complement data from randomized clinical trials by providing clinicians, researchers, and policy makers with information on the actual implementation and effect of BPH treatments in a broader population of patients.

The BPH Registry and Patient Survey (BRPS), an ongoing, prospective, observational multicentre, disease registry, is collecting clinical and outcome data on men with LUTS/BPH who are managed by a geographically diverse group of urologists and primary-care physicians in the USA. This report describes the design and methods of the BRPS and baseline demographic and clinical characteristics of enrolled men and their LUTS/BPH management.


The BRPS Steering Committee (see Acknowledgements), which comprises urologists, primary-care physicians, health services researchers, psychologists, and a biostatistician, was created to conceptualize the design and to oversee all scientific decisions on the conduct of the BRPS. A clinical research organization (i3 Research, Basking Ridge, NJ, USA) was contracted for data collection, database management and reporting. The BRPS is being conducted in accordance with Good Clinical Practice guidelines. Each principal investigator/physician was required to submit registry documents and obtain Institutional Review Board approval before performing any registry-related procedures. The BRPS is funded by Sanofi-Aventis.

The overall objectives of the BRPS are: (i) to examine physician management practices and patient outcomes, including symptom amelioration and disease progression; (ii) to gain a better understanding of the relationship between LUTS and sexual dysfunction in ageing men; (iii) to further validate the Men’s Sexual Health Questionnaire (MSHQ) [9]; and (iv) to provide a benchmark for clinical outcomes against regional and national results. The registry was planned to include ≈500 sites and ≈7500 men. Based on long-term data on overall clinical disease progression and the failure of medical therapy from the Medical Therapy of Prostate Symptoms trial [10], participants are scheduled to be followed for ≥2 years.

Physician management practices and patient characteristics and outcomes in the registry will be examined using descriptive statistics and various statistical models that address the relationship between a response/outcome and various exploratory variables. Clinical and quality-of-life measures will be assessed at baseline and at the follow-up, and expressed as the mean change from baseline. Analysis of covariance and regression models will be developed and the statistical significance of prognostic variables will be determined at the 0.05 level. Correlations between various clinical variables will be determined using Pearson product-moment and Spearman rank-order correlation. Demographic data and safety data will be summarized using descriptive statistics.

A geographically diverse group of USA urologists and primary-care physicians enrolled eligible men with LUTS/BPH (Fig. 1). We sought a ratio of urologists to primary-care physicians of ≈2 : 1; a maximum of 50 men could be enrolled at each investigational site. The primary inclusion criterion was a diagnosis of LUTS/BPH that was untreated (newly diagnosed or managed with watchful waiting, WW, or botanical products) or presently/recently treated with an α1-adrenergic blocker (AB), a 5α-reductase inhibitor (5ARI), a combination of an AB and a 5ARI, or anticholinergics. ‘Recently treated’ was defined as ABs not discontinued ≥1 month before enrolment and 5ARIs not discontinued ≥3 months before enrolment. Patients were excluded if they had concomitant LUT disease or carcinoma, a history of prostatic surgery, including minimally invasive procedures, isolated bladder neck disease or urethral stenosis/strictures, gross haematuria, current acute urinary retention, neurological disease or other condition that has a direct effect on urinary function, acute renal disease, or active liver disease, were using LHRH analogues or antiandrogens, or were currently enrolled in a clinical or research study. Patients follow the management plan developed in collaboration with their physicians throughout the registry, with no treatments or patient clinic/office visits specified by protocol.

Figure 1.

Investigational sites according to USA geographical region.

At enrolment (baseline visit), after explaining the protocol, obtaining informed consent, and providing the Health Insurance Portability and Accountability Act statement to enrolees, site investigators collected three types of data: (i) pre-enrolment data on current BPH management; (ii) baseline demographic and clinical information, overall assessments, and self-reported data on LUTS and LUTS bother, sexual function, and health-related quality of life using physician- and patient-completed forms and questionnaires; and (iii) data after enrolment on BPH management (Table 1) [9,11–14]. Follow-up visits are scheduled according to each physician’s usual procedure. Once enrolled, patients could continue their pre-enrolment therapy or switch to another medical therapy or WW, according to decisions made by the physician and/or patient. We sought a sample in which about a third of men were managed with WW, about a third were presently/recently treated, and about a third were switched from WW to treatment.

Table 1.  The assessments at the initial and follow-up visits
Form/QuestionnaireVisit 1Follow-up visits
Before enrolmentBaselineAfter enrolment
Physical Examination and X X
Treatment Form
Clinical History FormX XX
Serious Adverse Event Form   X
Baseline Form X  
Follow-up Form   X
IPSS/IPSS Bother [11] X X
BPH Impact Index [12] X X
MSHQ [9] X X
SHIM [13] X X
SF-12 [14] X  

At the baseline visit, each physician completed: (i) a Physical Examination and Treatment Form on each patient’s LUTS/BPH history and any treatment prescribed or continued; and (ii) a Clinical History Form on comorbidities, concomitant medications, and any reported adverse events (unsolicited common complaints). Each patient completed: (i) a Baseline Form on sociodemographic information; (ii) self-administered questionnaires, including the seven-item IPSS [11] (total score, 0–35, with scores of ≤7 indicating mild, of 8–19 indicating moderate, and of ≥20 indicating severe LUTS) and the IPSS Bother Question (score 0–6, with scores of ≤2 indicating mild, of 3 indicating moderate, and of ≥4 indicating severe bother); the four-item BPH Impact Index [12] (total score 0–12, with higher scores indicating a greater negative impact of BPH symptoms); the MSHQ [9], which includes a three-item erection domain (total score 1–15, with lower scores indicating decreased function), an erection bother question (score range of 0–5, with higher scores indicating greater bother), a seven-item ejaculation domain (total score 1–35, with lower scores indicating decreased function), an ejaculation bother question (score 0–5, with higher scores indicating greater bother), and a six-item satisfaction domain (total score 6–30, with lower scores indicating decreased satisfaction); the five-item Sexual Health Inventory for Men [13] (SHIM or International Index of Erectile Function-5), with a total score of 5–25, with scores of ≤21 indicating ED; the 12-Item Short Form Health Survey (SF-12) [14], with a Mental Component Score (MCS; score 0–100, with higher scores indicating better quality of life) and a Physical Component Score (PCS; score 0–100, with higher scores indicating better quality of life) that are standardized to a general USA population mean of 50 ± 10; and a Global Assessment Form (GAF) on the bother associated with urination problems and on satisfaction with sex life.

At each follow-up visit, each physician completes: (i) a Physical Examination and Treatment Form on LUTS/BPH history and any treatment prescribed or continued or any surgery since the last visit; (ii) a Clinical History Form on comorbid conditions, concomitant medications, and any patient-reported common complaints; and (iii) a Serious Adverse Event Form to describe any medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in significant disability/incapacity, is a congenital anomaly, or other medically important event. At each follow-up visit, each patient completes: (i) a Follow-up Form on health insurance, any discontinuations of medication, out-of-pocket expenses for treatment of urinary symptoms, and any visits to other doctors or the emergency room for urinary symptoms; and (ii) the self-administered IPSS, BPH Impact Index, MSHQ, SHIM, and GAF. If a patient does not have an in-office follow-up visit within 6 ± 1 months of the last visit, the follow-up forms and questionnaires are mailed to the patient with instructions for their completion. A Final Status Form is completed by the physician when a patient completes (i.e. the investigator is satisfied that patient fulfils all registry requirements) or discontinues from the BPRS. In cases of discontinuation, the physician records the reason for discontinuation (e.g. did not meet inclusion/exclusion criteria, withdrawal of consent, adverse event, lost to follow-up, patient referred to another physician, new diagnosis of bladder or prostate cancer, patient enrolled in clinical or research study, investigator discontinued participation in registry), if known.


The first patient was enrolled on 23 January 2004 and the last on 25 February 2005. Enrolment in the BPRS was closed on 28 February 2005. At the time of the present baseline analysis (6 June 2005), data were available for 6909 men who were enrolled at 402 sites (Table 2), with 4537 (66%) men seen by urologists and 2372 (34%) seen by primary-care physicians. As of the present analysis, 634 (9%) of the men had discontinued their participation in the registry, with withdrawal of consent (340 men) the most common reason for discontinuation.

Table 2. 
Patient disposition * and the demographic and socio-economic characteristics of enrolled men at baseline
Variable (N)N (%) patients or baseline value
  • *

    As of 6 June 2005;

  • †Health insurance categories are not mutually exclusive.

Patients enrolled6909 (100)
Patients discontinued 634 (9)
Reason for discontinuation
 Did not meet inclusion/exclusion criteria  46 (1)
 Withdrawal of consent 340 (5)
 Adverse event   3 (<1)
 Death  18 (<1)
 Lost to follow-up  81 (1)
 Investigator discretion  10 (<1)
 Referred to another physician   2 (<1)
 New diagnosis prostate/bladder cancer  50 (1)
 Enrolled in clinical/research study  10 (<1)
 Investigator discontinued registry  43 (1)
 Other  31 (<1)
Mean (sd) age, years (6787)  66 (10)
Age groups (6787)
 <50 406 (6)
 50–59 1391 (20)
 60–692346 (35)
 70–792029 (30)
 ≥80 615 (9)
BMI, kg/m2 (3236)
 <25 733 (23)
 25–291460 (45)
 ≥301043 (32)
Race/ethnicity (6463)
 White5379 (83)
 Black/African-American 614 (10)
 Hispanic/White 276 (4)
 Hispanic/Black  35 (1)
 Other 175 (3)
Personal status, (6481)
 Married/living with significant other5165 (80)
 Not married/living with significant other 1316 (20)
Educational status, (6355)
 < High school diploma 578 (9)
 High school diploma/equivalent1669 (26)
 Some college1535 (24)
 ≥ College degree2573 (40)
Annual household income, US$ (6033)
 <15 000 537 (9)
 15 000–29 9991033 (17)
 30 000–49 999 1416 (23)
 50 000–74 9991330 (22)
 75 000–149 9991335 (22)
 ≥150 000 382 (6)
Primary health insurance, (5062)
 Private 1613 (32)
 Medicare/supplemental3344 (66)
 Medicaid/veterans/military 617 (12)
 Self-pay/none 100 (20
 Drug coverage plan with co-pay 592 (12)
 Other 327 (6)
 Do not know  20 (<1)

The mean (range) age of the enrolled men at baseline was 66.0 (30–94) years and most (83%) were white (Table 2). Of 3236 men with body-mass index (BMI) data, 77% had a BMI of ≥25 kg/m2. Overall, ≈80% of the men were married or living with a partner, 64% had at least some education beyond a high school diploma, and 74% had household incomes of at least US$ 30 000.

At baseline, the mean time since the diagnosis of BPH was 4 (0–49) years, whereas the mean time since LUTS were first experienced was 5 (0–49) years; Table 3). Overall, 2065 (33%) of the 6184 men who completed the IPSS had mild LUTS (IPSS ≤7), 3218 (52%) had moderate LUTS (8–19), and 901 (15%) had severe LUTS (≥20). Of 5137 men who had a DRE, 2025 (39%) had a moderately or significantly enlarged prostate. Total PSA levels had a wide range of values (0.1–117.9 ng/mL), with a median of 1.9 ng/mL. In all, 6284 men (94%) had at least one comorbid condition at the baseline visit. The most common comorbidities were hypertension (53%), high cholesterol (45%) and sexual dysfunction (36%) (Table 3).

Table 3.  The clinical characteristics of the enrolled men at baseline
VariableNo. patientsBaseline value
  • *

    Comorbid conditions reported by at least 10% of all patients; comorbidities are not mutually exclusive.

Mean (sd):
time since first LUTS, years4595   5 (5)
time since BPH diagnosis, years5888   4 (5)
maximum urinary flow rate, mL/s1045  12 (7)
Prostate size (DRE), n (%)5137 
 normal  864 (17)
 slightly enlarged 2248 (44)
 moderately enlarged 1695 (33)
 significantly enlarged  330 (6)
total PSA, ng/mL5420   2.9 (4.4)
total IPSS (range 0–35)6184   11.6 (7.1)
IPSS bother score (range 0–6)6415   2.5 (1.5)
BPH Impact Index (range 0–12)6450   2.8 (2.8)
Comorbidities, N (%)*6284 
 allergies/cold/flu/congestion 1070 (15)
 arthritis 1357 (20)
 depression/anxiety/sleep disorder 1117 (16)
 diabetes 1196 (17)
 digestive tract disorder 1427 (21)
 general pain/inflammation  777 (11)
 heart disease/heart failure 1227 (18)
 high cholesterol 3094 (45)
 hypertension 3658 (53)
 erectile or other sexual dysfunction  2511 (36)

Before enrolment, 6653 (96%) of the 6909 men had data on their BPH management strategy, whereas 6667 (96%) had data on their strategy after enrolment. Before enrolment, 3258 (49%) of men with available data were managed with WW, 21% with selective ABs, 11% with non-selective ABs, 11% with ABs and 5ARIs, 6% with 5ARIs and 2% with anticholinergics. At the end of the enrolment visit, 42% of the men were managed with WW, and the respective percentages were 26%, 11%, 12%, 7% and 2%. Thus, the percentage of men who switched from WW to medical treatment at the baseline visit was only 7%, which was less than the a priori estimate of 33%. The percentage of men receiving a uroselective AB (alfuzosin or tamsulosin) increased from 21% before enrolment to 26% after, whereas the percentage of men receiving each of the other BPH management options was essentially unchanged.

The mean SHIM score at baseline was 16.5 (Table 4), indicating that on average the men had mild-to-moderate ED. The mean MSHQ erection domain score of 8.4 also suggested a mild-to-moderate degree of ED. Likewise, the mean MSHQ bother score indicated that the men were ‘a little bit’ to ‘moderately’ bothered by their ED. ED was also reported as a common complaint by 1312 (50%) of 2643 men with a complaint at the enrolment visit. The mean MSHQ ejaculation domain score was 24.1, and the mean MSHQ bother score was 4.0. Of 2643 men who reported a complaint at the baseline visit, 104 (4%) reported abnormal ejaculation and 158 (6%) reported reduced ejaculate volume. About half of men with a complaint of ED and two-thirds of those with a complaint of ejaculatory dysfunction were receiving medical therapy for their LUTS/BPH.

Table 4. 
Sexual function and quality of life of enrolled men at baseline
Variable (range)No. patientsMean (sd) score
  1. For all variables, a higher score indicates a better outcome.

MSHQ [9]
 Erection domain (1–15)5786 8.4 (4.4)
 Erection bother (0–5)5785 3.6 (1.3)
 Ejaculation domain (1–35)579524.1 (7.7)
 Ejaculation bother (0–5)5534 4.0 (1.2)
 Satisfaction domain (6–30)538222.5 (5.9)
SHIM [13] (5–25)561916.5 (6.6)
SF-12 [14]3726 
 MCS (0–100) 52.2 (9.2)
 PCS (0–100) 47.4 (9.7)

The mean PCS and MCS of the SF-12 (Table 4) suggested that the men had a similar quality of life at baseline as a general USA population. Of 6318 men who completed the GAF before enrolment, 33% reported that trouble with urination was ‘not at all bothersome’, 39% reported that it ‘bothers me a little’, and 28% indicated that it bothered them ‘some’ or ‘a lot’ during the past month. More men reported being satisfied with their sex lives than dissatisfied (43% were ‘very satisfied’ or ‘mostly satisfied’ with their sex lives, whereas 28% patients were ‘mostly dissatisfied’ or ‘very dissatisfied’).


At baseline, the men in the BPRS were predominantly aged >50 years, white, married and well-educated. Their common comorbidities include hypertension, high cholesterol and sexual dysfunction, with prevalence rates that are comparable to those in a population of USA men aged ≥50 years [4,15]. Men enrolled in the registry had a broad range of LUTS severity (33% mild, 52% moderate and 15% severe LUTS), which contrasts with most BPH clinical trials in which enrolment criteria pre-specify that men have moderate-to-severe LUTS. Thus, the men enrolled in the BPRS represent a USA population presenting with LUTS/BPH to urologists or primary-care physicians in everyday clinical practice, and can be longitudinally followed for their disease management and outcomes. Observation of this BPRS population might provide better insights on symptom progression, as a greater proportion of these men have mild LUTS than in standard BPH clinical trials. Only two other BPH-related registries, which monitor results of specific procedures in a few patients, the European Association of Urology Real Life Data Registry with Transurethral Needle Ablation Therapy [16] and the international registry for an interstitial laser device [17], were reported previously.

As there are now more older men because of the ageing of the population and increased life-expectancy, appropriate management and use of resources for chronic diseases, including LUTS/BPH, have become major challenges for the healthcare system. This, together with a change from primarily surgical procedures to medical therapy as the first-line management approach for LUTS/BPH, and from predominantly urologists to primary-care physicians as the initial healthcare providers managing men with LUTS/BPH, has created a need for a better understanding of current physician practice patterns and patient outcomes.

The longitudinal BPRS was initiated to provide a comprehensive database of information on physician practice patterns and health outcomes of men with BPH who are initially managed conservatively with either WW or medical therapy. Although evidence-based treatment guidelines exist on the management of LUTS/BPH [7], data are needed on any differences between these recommendations and actual treatment decisions in clinical practice settings. The role of possible confounding variables, including demographics, socio-economics, comorbidities, and physician speciality, also needs to be explored. The database from the BPRS should complement data derived from clinical trials and provide a different and unique real-world perspective on management practices and outcomes for LUTS/BPH.

Limitations of the BPRS include a selection bias of physicians, that might have occurred because physicians enrolling men in the registry were not randomly selected but rather chose to participate. Selection bias is also a possibility for the men enrolled in the registry, but the prevalence rates of various comorbidities (e.g. hypertension, high cholesterol) in the enrolled men suggests that they are generally representative of an ageing USA male population [4,15]. Data from registries can also be limited by having too few patients receiving certain interventions or by patients with mild disease who do not warrant medical therapy.

In conclusion, the BPRS will provide a comprehensive database of information for assessing risk factors for LUTS/BPH, current physician-practice patterns in the management of LUTS/BPH, and health outcomes of men with LUTS/BPH in the USA.


The members of the BPH Registry & Patient Survey Steering Committee are: Stanley E. Althof, Cleveland, Ohio; Steven Kaplan, New York, NY; Mark S. Litwin, Los Angeles, California; Michael Manyak, Washington, DC; Leonard S. Marks, Los Angeles, California; Kevin T. McVary, Chicago, Illinois; Charles Metzger, Glendora, California; Martin Miner, Swansea, Massachusetts; James Nuckolls, Roanoke, Virginia; Michael P. O’Leary, Boston, Massachusetts; David Pasta, San Francisco, California; Richard Payne, Encinitas, California; David Penson, Los Angeles, California; Michael Perelman, New York, NY; Claus G. Roehrborn, Dallas, Texas; Raymond C. Rosen, Piscataway, New Jersey; Allen D. Seftel, Cleveland, Ohio; William Steers, Charlottesville, Virginia; Alexis E. Te, New York, NY; John T. Wei, Ann Arbor, Michigan. The BPH Registry & Patient Survey is supported by sanofi-aventis, and all members of the BPH Registry & Patient Survey Steering Committee are paid consultants. Martin Miner, James Nuckolls, Richard Payne, William Steers, and John Wei also serve as site investigators for the BPH Registry & Patient Survey. Patricia B. Leinen, PhD (Tri-Medical Communications, Media, PA) contributed to the preparation of the manuscript.


Claus G Roehrborn has received honoraria as Co-Chairman of the BPH Registry, and in the past was Investigator for Sanofi Aventis; John Wei is a Paid Consultant and a Study Investigator for Sanofi Aventis; William Steers is on the Advisory Board and is a Paid Consultant for Sanofi Aventis, a Study Investigator for Nouratis and Allergan, and a Paid Consultant for Dynogen.